Listing of Claims:

Claims 1-14 (canceled)

Claim 15 (Currently Amended): A compound of the formula (I)

$$R_1$$
 R_2
 $N(R_5)(R_6)$
 R_7
 R_8

wherein

R₁ is H;

R₂ is H <u>or methyl;</u>, C₄-C₄alkyl-which is unsubstituted or substituted by one or more substituents selected from halogen, OH, SH, OCH₃, SCH₃, CN, SCN and nitro;

R₃ is methyl, H, -CF₃, -C₂F₅, -CH₂ Z or R₂ and R₃ together form with the nitrogen form a C₃-C₅heteroaliphatic ring;

Z is H, OH, F, CI, CH₃; CF₃, CH₂CI, CH₂F or CH₂OH;

 R_4 is C_1 - C_{16} straight chain alkyl, C_3 - C_{10} branched chain alkyl, -(CH_2)₀₋₆- C_3 - C_7 -cycloalkyl, -(CH_2)₁₋₆- Z_1 , -(CH_2)₀₋₆-phenyl, and -(CH_2)₀₋₆-het, wherein the alkyl, cycloalkyl and phenyl substituents are unsubstituted or substituted;

 $Z_1 \text{ is -N(R_9)-C(O)-C}_{10}\text{alkyl, -N(R_9)-C(O)-(CH}_{2})_{1.6}\text{-C}_{3}\text{-C}_{7}\text{-cycloalkyl, -N(R_9)-C(O)-(CH}_{2})_{0.6}\text{-phenyl, -N(R_9)-C(O)-(CH}_{2})_{1.6}\text{-het, -C(O)-N(R}_{10})(R_{11}), -C(O)\text{-O-C}_{1}\text{-C}_{10}\text{alkyl, -C(O)-O-(CH}_{2})_{1.6}\text{-het, -C-C(O)-O-(CH}_{2})_{1.6}\text{-het, -O-C(O)-C}_{10}\text{alkyl, -O-C(O)-(CH}_{2})_{1.6}\text{-het, -O-C(O)-(CH}_{2})_{1.6}\text{-het, wherein the alkyl, cycloalkyl and phenyl substituents are unsubstituted or substituted;}$

het is a 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon atom by halogen, hydroxy, C₁-C₄alkyl, C₁-C₄ alkoxy, nitro, -O-C(O)-C₁-C₄alkyl or -C(O)-O-C₁-C₄-alkyl or -C(O)-O-C₁-C₄-alkyl;

R₉ is H, -CH₃, -CF₃, -CH₂OH or CH₂CI;

 R_{10} and R_{11} are each independently H, C_1 - C_4 alkyl, C_3 - C_7 -cycloalkyl, -(CH_2)₁₋₆- C_3 - C_7 -cycloalkyl, -(CH_2)₀₋₆-phenyl, wherein the alkyl, cycloalkyl and phenyl substituents are unsubstituted or substituted, or R_{10} and R_{11} together with the nitrogen are het;

X is CH or N:

R₅ is H, C₁-C₁₀-alkyl, C₃-C₇-cycloalkyl, -(CH₂)_{1.6}-C₃-C₇-cycloalkyl, -C₁-C₁₀-alkyl-aryl, -(CH₂)_{0.6}-C₃-C₇-cycloalkyl-(CH₂)_{0.6}-phenyl, -(CH₂)_{0.4}CH-((CH₂)_{1.4}-phenyl)₂, -(CH₂)_{0.6}-CH(phenyl)₂, -C(O)-C₁-C₁₀alkyl, -C(O)-(CH₂)_{1.6}-C₃-C₇-cycloalkyl, -C(O)-(CH₂)_{0.6}-phenyl, -(CH₂)_{1.6}-het, -C(O)-(CH₂)_{1.6}-het, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted:

R₆ is H, methyl, ethyl, -CF₃, -CH₂OH or -CH₂Cl; or

R₅ and R₆ together with the nitrogen are het;

 R_7 and R_8 are cis relative to the acyl substituent at the one position of the ring and R_7 is H_1 - C_1 - C_{10} alkyl, -OH, -O- C_1 - C_{10} -alkyl, -(CH₂)₀₋₆- C_3 - C_7 -cycloalkyl, -O-(CH₂)₀₋₆-aryl, phenyl, - (CH₂)₁₋₆-het, -O-(CH₂)₁₋₆-het, -N(R₁₂)(R₁₃), -S-R₁₂, -S(O)-R₁₂, -S(O)₂-R₁₂, -S(O)₂-NR₁₂R₁₃ wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted; R_8 is -N(R₁₂)(R₁₃);

 R_{12} and R_{13} are independently H, C_1 - C_{10} alkyl, $-(CH_2)_{0-6}$ - C_3 - C_7 -cycloalkyl, $-(CH_2)_{0-6}$ - $(CH)_{0-1}(aryl)_{1-2}$, -C(O)- C_1 - C_{10} alkyl, -C(O)- $(CH_2)_{1-6}$ - C_3 - C_7 -cycloalkyl, -C(O)- $(CH_2)_{0-6}$ -aryl, -C(O)- $(CH_2)_{0-6}$ -aryl, -C(O)- $(CH_2)_{0-6}$ -aryl, -C(O)- $(CH_2)_{0-6}$ -aryl, -C(O)- $(CH_2)_{1-6}$ -het, wherein the alkyl, cycloalkyl and aryl substituents are unsubstituted or substituted; er-a substituent that facilitates transport of the molecule across a cell membrane, or R_{12} and R_{13} together with the nitrogen are het;

aryl is phenyl or naphthyl which is unsubstituted or substituted;

n is 0, 1 or 2;

and wherein

substituted alkyl substituents are substituted by one or more substituents selected from a double bond, halogen, OH, -O-C₁-C₆alkyl, -S-C₁-C₆alkyl and -CF₃;

substituted cycloalkyl substituents are substituted by one or more substituents selected from a double bond, C_1 - C_6 alkyl, halogen, OH, -O- C_1 - C_6 alkyl, -S- C_1 - C_6 alkyl and -CF₃, and substituted phenyl or aryl are substituted by one or more substituents selected from halogen, hydroxy, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, nitro, -CN, -O-C(O)- C_1 - C_4 alkyl and -C(O)-O- C_1 - C_4 -alkyl, or a pharmaceutically acceptable salt thereof.

Claim 16 (canceled): A compound of claim 15 wherein R₂ is H or methyl and R₃ is methyl.

Claim 17 (original): A compound of claim 15 wherein n is 1.

Claim 18 (original): A compound of claim 15 having the stereochemistry indicated in formula

$$R_1$$
 R_2
 $N(R_5)(R_6)$
 R_4
 $N(R_5)(R_6)$
 R_7
 R_8

Claim 19 (canceled): A compound of claim 18 wherein R2 is H or methyl and R3 is methyl.

Claim 20 (original): A compound of claim 18 wherein n is 1.

Claim 21 (original): A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I according to claim 15.

Claim 22 (original): A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula II according to claim 18.

Claim 23 (original): A pharmaceutical composition according to claim 21 for treating a proliferative disease.

Claim 24 (original): A pharmaceutical composition according to claim 22 for treating a proliferative disease.

Claim 25 - 28 (withdrawn).